<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083547</url>
  </required_header>
  <id_info>
    <org_study_id>CTC study</org_study_id>
    <nct_id>NCT04083547</nct_id>
  </id_info>
  <brief_title>Circulating Tumour Cells in Patients With Peritoneal Metastases</brief_title>
  <official_title>Cirkulerande Tumörceller Hos Patienter Med Bukhinnespridda tumörer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the prognostic value of circulating tumour cells (CTC) in
      patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy due
      to gastrointestinal cancers that have spread to the peritoneum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CTCs har extracted by way of a new method at baseline, during surgery, and postoperatively.
      The occurence of such CTCs will be investigated for prognostic evaluation. Patients will be
      follow-up by Clinical routine. Disease recurrence and overall survival will be the endpoint
      used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic value</measure>
    <time_frame>2 year.</time_frame>
    <description>Prediction of survival and recurrence according to the occurrence of CTCs.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Circulating Tumor Cell</condition>
  <condition>Peritoneal Metastases</condition>
  <condition>Hyperthermic Intraperitoneal Chemotherapy</condition>
  <arm_group>
    <arm_group_label>HIPEC group</arm_group_label>
    <description>All patients undergoing HIPEC will asked to join this prospective study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>iCellate</intervention_name>
    <description>New method of circulating tumour cell detection and capture.</description>
    <arm_group_label>HIPEC group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients being treated in Uppsala with CRS and HIPEC will be asked to join the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Peritoneal metastases being treated with cytoreductive surgery and hyperthermic
             intraperitoneal chemotherapy

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Cashin, MD PhD</last_name>
    <phone>+46 186174304</phone>
    <email>peter.cashin@surgsci.uu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akademiska Sjukhuset (Uppsala University hospital)</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Cashin, M.D. Ph.D</last_name>
      <phone>+46 18 6174304</phone>
      <email>peter.cashin@surgsci.uu.se</email>
    </contact>
    <investigator>
      <last_name>Peter Cashin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christer Ericsson, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

